A public record of what is known, what is claimed, and what is not.

Health

1 record

JUL

No. 008Health

Verecor reports Phase 3 migraine-prevention results: 1.3 fewer monthly migraine days than placebo

Verecor Therapeutics published topline Phase 3 results on July 7 for its migraine-prevention drug velartinib: across 1,204 participants over 12 weeks, the treatment group averaged 4.2 fewer monthly migraine days versus 2.9 for placebo, a difference of 1.3 days.

3 Confirmed
1 Attributed
1 Disputed
2 Unknown

← NewerPage 1 of 1Older →

End of the record

1 entries

There is no page after the last one. No ranking, no recommendations, no infinite scroll — the feed is chronological and it ends.